Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.31 |
| ▸ | KDM4A | O75164 | 2/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.31 |
| ▸ | TET3 | O43151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969192 | 0.97 | LMNA (0.37) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL23111822 | 0.95 | TSHR (0.39) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL23355066 | 0.90 | KDM2A (0.33) | LMNATET2KDM4AKDM4CKDM2A | |
| SCHEMBL7895528 | 0.84 | TSHR (0.44) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL2019309 | 0.81 | LMNA (0.41) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL3223948 | 0.79 | TSHR (0.43) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL7905680 | 0.78 | TSHR (0.40) | TSHRSLC22A6 | |
| SCHEMBL9980489 | 0.77 | NAAA (0.35) | — | |
| SCHEMBL6025638 | 0.75 | — | — | |
| SCHEMBL4786240 | 0.75 | TRPA1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4009857-B1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORP (US) | 2025-08-20 | — | — | EP | claimed |
| US-20250041485-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION | 2025-02-06 | — | — | US | claimed |
| US-12151048-B2 | Bioerodible cross-linked hydrogel implants and related methods of use | DOSE MEDICAL CORPORATION (US) | 2024-11-26 | — | — | US | claimed |
| US-20220323650-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION | 2022-10-13 | — | — | US | claimed |
| US-11383006-B2 | Bioerodible cross-linked hydrogel implants and related methods of use | DOSE MEDICAL CORPORATION (US) | 2022-07-12 | — | — | US | claimed |
| EP-4009857-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE Medical Corporation (US) | 2022-06-15 | — | — | EP | claimed |
| EP-3976124-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE Medical Corporation (US) | 2022-04-06 | — | — | EP | claimed |
| WO-2021026214-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION (US) | 2021-02-11 | — | — | WO | claimed |
| US-20210038769-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION | 2021-02-11 | — | — | US | claimed |
| WO-2020243602-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION (US) | 2020-12-03 | — | — | WO | claimed |
| US-20200375891-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORP (US) | 2020-12-03 | — | — | US | claimed |
| US-20250041475-A1 | MEDICAL TISSUE ADHESIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING BIOSIS HEALING BIOLOGICAL TECHNOLOGY CO., LTD (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4450095-A1 | MEDICAL TISSUE ADHESIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Biosis Healing Biological Technology Co., Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| EP-3793622-A1 | EMBOLIC COMPOSITIONS AND METHODS | Incept, LLC (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2017015616-A1 | OCULAR PROTEIN DELIVERY | ENVISIA THERAPEUTICS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2004049914-A2 | METHODS FOR REACTING AN ANTIGEN MASKING COMPOUND WITH RED BLOOD CELLS WITH HIGH EFFICIENCY | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050897-A2 | METHODS FOR PREPARING ANTIGEN MASKED RED BLOOD CELLS HAVING REDUCED HEMOLYSIS BY SERA | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050848-A2 | METHODS FOR ANTIGEN MASKING OF RED BLOOD CELLS RESULTING IN REDUCED HEMOLYSIS | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-1996021036-A2 | NUCLEIC ACID CONDENSING AGENTS WITH REDUCED IMMUNOGENICITY | CHIRON VIAGENE, INC. (US) | 1996-07-11 | — | — | WO | disclosed |